Product image of Insulatard (Insulin Human) supplied by GNH India

Insulatard

Active Ingredient:
Insulin Human
Origin:
EU

Insulatard (Insulin Human)

Insulin Human, the active ingredient in Insulatard, is a recombinant human insulin classified as an intermediate‑acting insulin presented as an injectable suspension for subcutaneous administration. It is used to lower elevated blood glucose levels in patients with diabetes mellitus, providing basal insulin support for both type 1 and type 2 diabetes.

GNH India supplies Insulatard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled shipments that meet regulatory standards across multiple markets and providing dedicated technical support for product handling.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insulatard is an intermediate‑acting insulin used in the management of diabetes mellitus and related insulin‑deficiency conditions.

  • Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels.
  • Type 2 diabetes mellitus: used as basal insulin when oral agents no longer achieve target glycaemia.
  • Insulin deficiency states: supplies exogenous insulin to replace absent endogenous insulin and prevent hyperglycaemia.

How It Works

  • Insulin Human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This stimulates translocation of GLUT‑4 transporters, enhances glucose uptake, and suppresses hepatic gluconeogenesis, thereby reducing circulating blood glucose concentrations.

Side Effects

Insulatard may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Hypoglycaemia: low blood sugar episodes, especially if meals are missed or dosing is excessive.
  • Injection site reactions: redness, swelling or itching at the injection site.
  • Weight gain: increased caloric storage associated with improved glucose utilisation.
  • Edema: peripheral fluid accumulation, often mild.

Serious or Rare Side Effects

  • Severe hypoglycaemia leading to seizures or loss of consciousness.
  • Allergic reactions: urticaria, angio‑edema or anaphylaxis.
  • Insulin antibody formation: may alter insulin action and cause unpredictable glucose control.

Precautions & Warnings

When using Insulatard, clinicians and patients should observe several safety measures.

  • Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycaemia.
  • Dose adjustment during illness: reduce or increase dose based on carbohydrate intake and stress response.
  • Avoid use in active hypoglycaemia: do not administer if blood glucose is already low.
  • Caution in renal or hepatic impairment: impaired clearance may increase insulin effect.
  • Pregnancy and lactation: use only if benefits outweigh potential risks; consult a specialist.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the suspension.

Avoid Interactions

Insulatard can interact with several drug classes, influencing glucose control.

Major Interactions (Avoid)

  • Sulfonylureas: combined effect may cause severe hypoglycaemia.
  • Meglitinides: additive glucose‑lowering effect increases hypoglycaemia risk.
  • Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: may enhance insulin sensitivity, requiring dose review.
  • Thiazide diuretics: can raise blood glucose, potentially reducing insulin efficacy.
  • Corticosteroids: increase glucose production, possibly necessitating higher insulin doses.

Frequently Asked Questions

Insulatard is a basal insulin formulation containing insulin human. It is prescribed to provide long‑lasting glucose control in patients with type 1 diabetes, type 2 diabetes requiring basal insulin, and other conditions where endogenous insulin production is insufficient.

Insulin human mimics the action of natural human insulin. It binds to insulin receptors on muscle, fat and liver cells, triggering a cascade that moves glucose into cells for energy and suppresses glucose production by the liver, thereby lowering blood sugar levels.

The dose of Insulatard is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s blood‑glucose profile, body weight, diet, activity level and other medications.

Safety data are limited, and the pregnancy category is not definitively established. Insulin is generally considered the preferred glucose‑lowering therapy in pregnancy, but use of Insulatard should be decided by a healthcare professional after weighing potential benefits and risks.

To order Insulatard, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Insulatard is an intermediate‑acting insulin with a slower onset and longer duration than rapid‑acting analogues, but a shorter profile than ultra‑long‑acting basal insulins such as insulin glargine. It offers a cost‑effective option for basal coverage, especially in markets where biosimilar human insulin is preferred.

Insulatard must be stored at 2‑8 °C (refrigerated) in its original container, protected from light. Do not freeze or shake the suspension. If needed, it may be kept at controlled room temperature (up to 25 °C) for a maximum of 28 days, after which any unused portion should be discarded.

Insulatard is given by subcutaneous injection, usually into the abdomen, thigh or upper arm. It is administered once or twice daily, depending on the prescribed regimen, and should be injected into a different site each time to reduce the risk of lipohypertrophy.

The most serious risks include severe hypoglycaemia, which can cause seizures or loss of consciousness, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognising early signs of low blood sugar and instructed to seek immediate medical attention for any severe reaction.

Insulatard should not be used by individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It is also contraindicated in patients experiencing an active episode of hypoglycaemia until glucose levels are corrected.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT